Guardant
Stage
IPOTotal Raised
$450MInvestors Count
35Deal Terms
6Portfolio Exits
1Investments
2Funding, Valuation & Revenue
9 Fundings
Guardant has raised $450M over 9 rounds.
Guardant's latest funding round was a IPO for $237.5M on October 4, 2018.
Guardant's latest post-money valuation is from October 2018.
Sign up for a free demo to see Guardant's valuations in October 2018 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
10/4/2018 | IPO | $237.5M | 4 | |||
5/11/2017 | Series E | |||||
1/7/2016 | Series D | |||||
2/3/2015 | Series C | |||||
1/1/2015 | Series B - II |
Date | 10/4/2018 | 5/11/2017 | 1/7/2016 | 2/3/2015 | 1/1/2015 |
|---|---|---|---|---|---|
Round | IPO | Series E | Series D | Series C | Series B - II |
Amount | $237.5M | ||||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 4 |
Guardant Deal Terms
6 Deal Terms
Guardant's deal structure is available for 6 funding rounds, including their IPO from October 04, 2018.
Round | IPO | Series E | Series D | Series C | Series B |
|---|---|---|---|---|---|
Funding Date | |||||
Pre-Money Valuation | |||||
Post-Money Valuation | |||||
Amount Raised | |||||
Shares Authorized | |||||
Issuance Price | |||||
Dividend Rate | |||||
Liquidation Preferences | |||||
Liquidation Price | |||||
Participation | |||||
Conversion Price | |||||
Anti Dilution | |||||
General Voting | |||||
Board Voting | |||||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IPO | |||||||||||||||
Series E | |||||||||||||||
Series D | |||||||||||||||
Series C | |||||||||||||||
Series B |
Guardant Investors
35 Investors
Guardant has 35 investors. Sequoia Capital invested in Guardant's Series E funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
4/22/2013 | 5/11/2017 | 5 Series A, Series B (2014), Series C (2015), Series D (2016), Series E (2017) | Venture Capital | California | ||
4/22/2014 | 5/11/2017 | 4 Series B, Series C (2015), Series D (2016), Series E (2017) | Venture Capital | California | ||
2/3/2015 | 5/11/2017 | 3 Series C, Series D (2016), Series E (2017) | Venture Capital | California | ||
Venture Capital | New York | |||||
Public-Private Partnership | Singapore |
First funding | 4/22/2013 | 4/22/2014 | 2/3/2015 | ||
|---|---|---|---|---|---|
Last Funding | 5/11/2017 | 5/11/2017 | 5/11/2017 | ||
Investor | |||||
Rounds | 5 Series A, Series B (2014), Series C (2015), Series D (2016), Series E (2017) | 4 Series B, Series C (2015), Series D (2016), Series E (2017) | 3 Series C, Series D (2016), Series E (2017) | ||
Board Seats | |||||
Type | Venture Capital | Venture Capital | Venture Capital | Venture Capital | Public-Private Partnership |
Location | California | California | California | New York | Singapore |
Guardant Acquisitions
3 Acquisitions
Guardant acquired 3 companies. Their latest acquisition was MetaSight on December 01, 2025.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
12/1/2025 | Other Venture Capital | Acquired | 3 | |||
6/13/2022 | ||||||
3/27/2019 | Seed / Angel |
Date | 12/1/2025 | 6/13/2022 | 3/27/2019 |
|---|---|---|---|
Investment Stage | Other Venture Capital | Seed / Angel | |
Companies | |||
Valuation | |||
Total Funding | |||
Note | Acquired | ||
Sources | 3 |
Guardant Investments
2 Investments
Guardant has made 2 investments. Their latest investment was in ObvioHealth as part of their Series B - IV on July 25, 2024.
Guardant Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
7/25/2024 | Series B - IV | ObvioHealth | $18.4M | Yes | 4 | |
7/19/2021 | Series C - II |
Date | 7/25/2024 | 7/19/2021 |
|---|---|---|
Round | Series B - IV | Series C - II |
Company | ObvioHealth | |
Amount | $18.4M | |
New? | Yes | |
Co-Investors | ||
Sources | 4 |
Guardant Portfolio Exits
1 Portfolio Exit
Guardant has 1 portfolio exit. Their latest portfolio exit was Lunit on July 21, 2022.
Compare Guardant to Competitors
Freenome operates as a biotechnology company specializing in early cancer detection within the healthcare sector. The company develops blood tests that use multiomics technology and artificial intelligence to identify cancer at its earliest and most treatable stages. It was founded in 2014 and is based in Brisbane, California.
Owlstone Medical focuses on breath analysis for disease detection within the healthcare sector. The company develops technology for discovering and validating biomarkers in breath, employing chemical analysis and sensor technology for diagnosis. Owlstone Medical's products and services are intended for academic, clinical, and pharmaceutical research partners involved in developing breath-based diagnostics. It was founded in 2004 and is based in Cambridge, United Kingdom.
OncoTAB is a biotechnology company involved in cancer diagnostics and therapeutics. The company provides a blood test, Agkura4 Personal Score, that measures levels of a tumor-associated protein to assist in the early detection of breast cancer in women with dense breast tissue. Additionally, OncoTAB develops treatments for breast and pancreatic cancers. It is based in Charlotte, North Carolina.
Liquid Genomics provides testing services for the detection of cancer gene mutations through blood-based testing within the healthcare and biotechnology sectors. The company utilizes digital PCR and allele-specific blocker PCR technologies to identify and quantify mutations in blood or tissue samples. Its services are aimed at the healthcare industry, focusing on cancer diagnostics and research. It is based in Torrance, California.
AccuraGen specializes in cancer diagnostics within the biomedical sector, focusing on the development of liquid biopsy technology. The company offers diagnostic solutions that utilize DNA and RNA sequencing for personalized medicine, allowing for non-invasive cancer detection and monitoring. AccuraGen's rolling-circle amplification technology improves genetic alteration detection, which is important for early cancer screening and minimal residual disease monitoring. It is based in Menlo Park, California.
CirculoGene Diagnostics operates within the healthcare sector, focusing on cancer detection and monitoring. The company provides genomic profiling of solid tumors at various stages, utilizing techniques like next-generation sequencing and polymerase chain reaction to analyze circulating free DNA and RNA. CirculoGene Diagnostics serves the healthcare and oncology sectors, offering products for the personalization and monitoring of cancer treatment plans. CirculoGene Diagnostics was formerly known as CirculoGene Theranostics, LLC. It was founded in 2015 and is based in Birmingham, Alabama.
Loading...